StockIQ.techViatris Inc. (VTRS) Stock Analysis
Free AI-powered analysis and research for Viatris Inc. stock
Sector: Healthcare
VTRS snapshot
Data as of 3 Nov 2026 close. Updated daily.
Viatris Inc. scores 65/100 on StockIQ's model, which reads as positive signals overall. The price is above its 200-day average and at 92% of its 52-week range, up 78.3% over the past year. Latest reported figures show a profit margin of -2.8%, return on equity of -2.8% and revenue growth of +4.9%.
What is driving the score
- RSI Neutral: +5
- Strong Uptrend: +12
- MACD Bullish: +8
- Unprofitable (-2.8%): -15
- Negative ROE (-2.8%): -10
- Strong Long-term Uptrend: +8
- Strong Rise (+78.3% over 1 year): +10
- Low Volume (0.3x): -3
Automated, general information only – not financial advice. Scores can be wrong. How the score works
Full VTRS report
Viatris Inc. (VTRS) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.
Analyze VTRS Now →📰 Latest Update
Viatris Gears Up to Report Q3 Earnings: Is a Beat in the Cards?
Tue, November 3, 2026 at 1:51 PM UTC 3 min read
Viatris (VTRS) is anticipated to report third-quarter earnings on Nov. 5, with expectations of beating estimates of $3.78 billion in revenue and 64 cents per share in earnings. The company is expected to see growth in Developed Markets driven by new product sales, although pressures from Dymista and EpiPen may offset gains. Despite challenges in Emerging Markets and JANZ due to supply constraints and competition, Viatris has shown a strong year-to-date stock performance, rising 50%.